The new direction taken in this competitive renewal comes from our longstanding interest in the signaling mechanisms of the pleiotropic cytokine TNF. While TNF-induced NF-?B activation and apoptosis are known for years, recent elucidation of TNF-induced programmed necrosis and the switching mechanisms among these three alternative cell fates have revolutionized how we look at this classical cytokine. In a simplified overview, RIP1 is at the center of this cell fate regulation. When RIP1 is ubiquitinated in the TNF signaling complex, NF-?B activation ensues, resulting in cell survival, proliferation and differentiation. When RIP1 ubiquitination is blocked by removal of the E3 ligases cIAP1 and cIAP2 through genetic ablation, RNAi knock down, or IAP antagonists, RIP1 forms a secondary complex with FADD and caspase-8 to initiate apoptotic cell death. If apoptosis is inhibited by caspase inhibitors or under certain physiological conditions, RIP1 associates with RIP3 to form the necrosome to initiate programmed necrosis or necropolis. Whereas necrosis was originally thought to be associated with non-specific cellular damage, recent evidence clearly showed that necrosis is critical for embryonic development, host defense and other biological processes. Despite the biological importance of the necrosome in the signal transduction of TNF and other death receptors, no structural and mechanistic information is available. In this application, we propose to assemble the RIP1/RIP3 necrosome and related complexes and to elucidate the molecular basis of the signal transduction.

Public Health Relevance

Engagement of the necrotic pathway in appropriate physiological contexts is important for embryonic development and initiates protective immune responses. However, the complexity of this pathway also renders itself susceptible to interruption and dysregulation, leading to its association with many human diseases, such as susceptibility to viral infection and unwanted cell death in ischemic injury in heart attack and stroke. Understanding this pathway at the molecular level would contribute to both health and disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI045937-12
Application #
8511536
Study Section
Special Emphasis Panel (ZRG1-IMM-M (08))
Program Officer
Leitner, Wolfgang W
Project Start
1999-07-01
Project End
2017-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
12
Fiscal Year
2013
Total Cost
$465,973
Indirect Cost
$169,952
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Li, Jixi; Yin, Qian; Wu, Hao (2013) Structural basis of signal transduction in the TNF receptor superfamily. Adv Immunol 119:135-53
Wu, Hao (2013) Higher-order assemblies in a new paradigm of signal transduction. Cell 153:287-92
Napetschnig, Johanna; Wu, Hao (2013) Molecular basis of NF-*B signaling. Annu Rev Biophys 42:443-68
Lu, Timothy T; Onizawa, Michio; Hammer, Gianna E et al. (2013) Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity 38:896-905
Zheng, Chao; Yin, Qian; Wu, Hao (2011) Structural studies of NF-*B signaling. Cell Res 21:183-95
Zheng, Chao; Kabaleeswaran, Venkataraman; Wang, Yaya et al. (2010) Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol Cell 38:101-13
Pan, Wei; da Graca, Li S; Shao, Yufang et al. (2009) PHAPI/pp32 suppresses tumorigenesis by stimulating apoptosis. J Biol Chem 284:6946-54
Yin, Qian; Lin, Su-Chang; Lamothe, Betty et al. (2009) E2 interaction and dimerization in the crystal structure of TRAF6. Nat Struct Mol Biol 16:658-66
Yin, Qian; Lamothe, Betty; Darnay, Bryant G et al. (2009) Structural basis for the lack of E2 interaction in the RING domain of TRAF2. Biochemistry 48:10558-67
Lin, Su-Chang; Chung, Jee Y; Lamothe, Betty et al. (2008) Molecular basis for the unique deubiquitinating activity of the NF-kappaB inhibitor A20. J Mol Biol 376:526-40

Showing the most recent 10 out of 20 publications